Cargando…

Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs)

Previous studies have now well-established that epithelial cancer cells can utilize ketone bodies (3-hydroxybutyrate and aceto-acetate) as mitochondrial fuels, to actively promote tumor growth and metastatic dissemination. The two critical metabolic enzymes implicated in this process are OXCT1 and A...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozsvari, Bela, Sotgia, Federica, Simmons, Katie, Trowbridge, Rachel, Foster, Richard, Lisanti, Michael P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667966/
https://www.ncbi.nlm.nih.gov/pubmed/29108233
http://dx.doi.org/10.18632/oncotarget.21259
_version_ 1783275584765296640
author Ozsvari, Bela
Sotgia, Federica
Simmons, Katie
Trowbridge, Rachel
Foster, Richard
Lisanti, Michael P.
author_facet Ozsvari, Bela
Sotgia, Federica
Simmons, Katie
Trowbridge, Rachel
Foster, Richard
Lisanti, Michael P.
author_sort Ozsvari, Bela
collection PubMed
description Previous studies have now well-established that epithelial cancer cells can utilize ketone bodies (3-hydroxybutyrate and aceto-acetate) as mitochondrial fuels, to actively promote tumor growth and metastatic dissemination. The two critical metabolic enzymes implicated in this process are OXCT1 and ACAT1, which are both mitochondrial proteins. Importantly, over-expression of OXCT1 or ACAT1 in human breast cancer cells is sufficient to genetically drive tumorigenesis and/or lung metastasis, validating that they indeed behave as metabolic “tumor promoters”. Here, we decided to target these two enzymes, which give cancer cells the ability to recycle ketone bodies into Acetyl-CoA and, therefore, to produce increased ATP. Briefly, we used computational chemistry (in silico drug design) to select a sub-set of potentially promising compounds that spatially fit within the active site of these enzymes, based on their known 3D crystal structures. These libraries of compounds were then phenotypically screened for their effects on total cellular ATP levels. Positive hits were further validated by metabolic flux analysis. Our results indicated that four of these compounds effectively inhibited mitochondrial oxygen consumption. Two of these compounds also induced a reactive glycolytic phenotype in cancer cells. Most importantly, using the mammosphere assay, we showed that these compounds can be used to functionally inhibit cancer stem cell (CSC) activity and propagation. Finally, our molecular modeling studies directly show how these novel compounds are predicted to bind to the active catalytic sites of OXCT1 and ACAT1, within their Coenzyme A binding site. As such, we speculate that these mitochondrial inhibitors are partially mimicking the structure of Coenzyme A. Thus, we conclude that OXCT1 and ACAT1 are important new therapeutic targets for further drug development and optimization. We propose that this new class of drugs should be termed “mitoketoscins”, to reflect that they were designed to target ketone re-utilization and mitochondrial function.
format Online
Article
Text
id pubmed-5667966
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56679662017-11-04 Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs) Ozsvari, Bela Sotgia, Federica Simmons, Katie Trowbridge, Rachel Foster, Richard Lisanti, Michael P. Oncotarget Research Paper Previous studies have now well-established that epithelial cancer cells can utilize ketone bodies (3-hydroxybutyrate and aceto-acetate) as mitochondrial fuels, to actively promote tumor growth and metastatic dissemination. The two critical metabolic enzymes implicated in this process are OXCT1 and ACAT1, which are both mitochondrial proteins. Importantly, over-expression of OXCT1 or ACAT1 in human breast cancer cells is sufficient to genetically drive tumorigenesis and/or lung metastasis, validating that they indeed behave as metabolic “tumor promoters”. Here, we decided to target these two enzymes, which give cancer cells the ability to recycle ketone bodies into Acetyl-CoA and, therefore, to produce increased ATP. Briefly, we used computational chemistry (in silico drug design) to select a sub-set of potentially promising compounds that spatially fit within the active site of these enzymes, based on their known 3D crystal structures. These libraries of compounds were then phenotypically screened for their effects on total cellular ATP levels. Positive hits were further validated by metabolic flux analysis. Our results indicated that four of these compounds effectively inhibited mitochondrial oxygen consumption. Two of these compounds also induced a reactive glycolytic phenotype in cancer cells. Most importantly, using the mammosphere assay, we showed that these compounds can be used to functionally inhibit cancer stem cell (CSC) activity and propagation. Finally, our molecular modeling studies directly show how these novel compounds are predicted to bind to the active catalytic sites of OXCT1 and ACAT1, within their Coenzyme A binding site. As such, we speculate that these mitochondrial inhibitors are partially mimicking the structure of Coenzyme A. Thus, we conclude that OXCT1 and ACAT1 are important new therapeutic targets for further drug development and optimization. We propose that this new class of drugs should be termed “mitoketoscins”, to reflect that they were designed to target ketone re-utilization and mitochondrial function. Impact Journals LLC 2017-09-24 /pmc/articles/PMC5667966/ /pubmed/29108233 http://dx.doi.org/10.18632/oncotarget.21259 Text en Copyright: © 2017 Ozsvari et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Ozsvari, Bela
Sotgia, Federica
Simmons, Katie
Trowbridge, Rachel
Foster, Richard
Lisanti, Michael P.
Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs)
title Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs)
title_full Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs)
title_fullStr Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs)
title_full_unstemmed Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs)
title_short Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs)
title_sort mitoketoscins: novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (cscs)
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667966/
https://www.ncbi.nlm.nih.gov/pubmed/29108233
http://dx.doi.org/10.18632/oncotarget.21259
work_keys_str_mv AT ozsvaribela mitoketoscinsnovelmitochondrialinhibitorsfortargetingketonemetabolismincancerstemcellscscs
AT sotgiafederica mitoketoscinsnovelmitochondrialinhibitorsfortargetingketonemetabolismincancerstemcellscscs
AT simmonskatie mitoketoscinsnovelmitochondrialinhibitorsfortargetingketonemetabolismincancerstemcellscscs
AT trowbridgerachel mitoketoscinsnovelmitochondrialinhibitorsfortargetingketonemetabolismincancerstemcellscscs
AT fosterrichard mitoketoscinsnovelmitochondrialinhibitorsfortargetingketonemetabolismincancerstemcellscscs
AT lisantimichaelp mitoketoscinsnovelmitochondrialinhibitorsfortargetingketonemetabolismincancerstemcellscscs